Key Metrics
CiteScore 

18.4
Impact Factor 

>= 25
Scite Index 

0.93 5-Year SI

SJR 

Q1Genetics

SNIP 

3.98
Recommended pre-submission checks
Powered by 

Topics Covered on Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | SPRINGERNATURE |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2690 | USD 3190 | GBP 2390 |
| Publication Time | 5 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Sichuan University |
| Frequency | Continuous publication |
| Publication Start Year | 2016 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in Signal Transduction and Targeted Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Signal Transduction and Targeted Therapy
Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer
- 7 Aug 2026
- Signal Transduction and Targeted Therapy
Calr-mediated calcium buffering: a molecular barrier to in vivo cardiac reprogramming
- 7 Aug 2026
- Signal Transduction and Targeted Therapy
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study
- 6 Aug 2026
- Signal Transduction and Targeted Therapy
RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target
- 6 Aug 2026
- Signal Transduction and Targeted Therapy
RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model
- 5 Aug 2026
- Signal Transduction and Targeted Therapy
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets
- 5 Aug 2026
- Signal Transduction and Targeted Therapy
Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer
- 7 Aug 2026
- Signal Transduction and Targeted Therapy
Calr-mediated calcium buffering: a molecular barrier to in vivo cardiac reprogramming
- 7 Aug 2026
- Signal Transduction and Targeted Therapy
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study
- 6 Aug 2026
- Signal Transduction and Targeted Therapy
RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target
- 6 Aug 2026
- Signal Transduction and Targeted Therapy
RAF1 extrachromosomal DNA amplification confers acquired erlotinib resistance in a non-small cell lung cancer cell model
- 5 Aug 2026
- Signal Transduction and Targeted Therapy
Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets
- 5 Aug 2026
- Signal Transduction and Targeted Therapy